Authorised uses of cancer medicine Yondelis unchanged following review of new data

View source ↗

Summary

The EMA review concluded that the authorised uses of Yondelis (trabectedin) remain unchanged after evaluating new data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Leiomyosarcoma
• Liposarcoma
• Ovarian Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Yondelis (trabectedin)